Medistim ASA (FRA:MD1) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:MD1 Medistim ASA FRA:MD1
100 GF Score
Price €19.90
GF Value €23.04
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Notes Receivable?

Medistim ASA FRA:MD1 -1.49% 100 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:MD1 with a GF Score™ of 100/100 and a GF Value™ of €23.04 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Medistim ASA's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Medistim ASA Notes Receivable Historical Data

* Premium members only.

The historical data trend for Medistim ASA's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Notes Receivable Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medistim ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:MD1
100GF Score
Medistim ASA FRA:MD1
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Medistim ASA (FRA:MD1) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Medistim ASA and its competitors.
Is Medistim ASA's Notes Receivable too high?
Medistim ASA's current Notes Receivable is €0.00 Mil. Overall, Medistim ASA has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Notes Receivable compare to ABT and SYK?
Medistim ASA's Notes Receivable of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Medistim ASA and its competitors. Medistim ASA's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Modestly Undervalued. The stock's GF Value™ is €23.04, compared to a current price of €19.90 — trading 13.6% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Medistim ASA's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (FRA:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €19.90 is trading 13.6% below its estimated GF Value™ of €23.04. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for FRA:MD1:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €23.04 vs. price of €19.90 (13.6% below fair value)
  • GF Score™: 100/100 with 1 warning sign

No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score

Get the complete analysis for FRA:MD1

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.90
Price
€23.04
GF Value